US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Emera Inc.

50.08

-1.7000-3.28%

Pre-market: 53.783.70+7.38%04:01 EDT

Volume:487.92K

Turnover:24.66M

Market Cap:15.31B

PE:22.46

High:51.91

Open:51.91

Low:50.03

Close:51.78

52wk High:55.49

52wk Low:45.77

Shares:305.78M

Float Shares:305.78M

Volume Ratio:1.75

T/O Rate:0.16%

Dividend:2.11

Dividend Rate:4.22%

EPS(TTM):2.23

EPS(LYR):2.47

ROE:7.56%

ROA:2.91%

PB:1.64

PE(LYR):20.32

Loading ...

Overview Company News Filings

Press Release: Ipsen delivers strong sales in the first quarter of 2026 and confirms its full-year guidance

Bitcoin, Ethereum, XRP, Dogecoin Up 3% As Markets Hope For Iran War Settlement

Capricor Therapeutics Announces Late-Breaking Presentation of HOPE-3 Phase 3 Results at the American Academy of Neurology 2026 Annual Meeting

Emera price target raised to C$73 from C$72 at CIBC

S&P 500 Futures Drop In Premarket Trading; TopBuild, Imperial Oil Lead

Singapore procuring more LNG as Iran war cuts some supply

Sing Yee Ong & Stephen Stapczynski / Bloomberg

Roche Initiates New Study for Elevidys Gene Therapy Following European Regulatory Feedback

Press Release: Emera Incorporated Announces Dividend Rates for Series J and Series K First Preferred Shares

Why Infleqtion Stock Trading Higher On Wednesday?

Benzinga_recent_news

Suzhou Ribo Advances Lead siRNA Anticoagulant With EMA Phase 2b Filing

Emera Maintains Quarterly Dividend at $0.7325 per Share; Payable Around May 15 to Shareholders of Record on May 1

MT Newswires Live

Press Release: Emera Declares Quarterly Dividends

Press Release: Emera Teleconference on May 8 to Discuss Q1 2026 Results

Oculis to Participate in Upcoming Investor Conferences

How Investors Are Reacting To Teva (TEVA) Advancing Its Biosimilar Pipeline With New FDA and EMA Milestones

Simply Wall St.

Is EMA Validation Of Taletrectinib Expanding Nuvation Bio’s (NUVB) Targeted Lung Cancer Opportunity?

Simply Wall St.

ABBISKO-B Shares Surge Nearly 10% on EMA Orphan Drug Designation for FGFR4 Inhibitor

Press Release: BrainStorm Cell Therapeutics Announces Full Year 2025 Financial Results and Provides Corporate Update

Abbisko Wins EMA Orphan Drug Status for Liver Cancer Therapy Irpagratinib

ABBISKO-B (02256): FGFR4 Inhibitor Irpagratinib Receives Orphan Drug Designation from EMA for Hepatocellular Carcinoma Treatment

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/EMA/news?page=10"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"EMA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMA\",,,,,undefined,":{"symbol":"EMA","market":"US","secType":"STK","nameCN":"Emera Inc.","latestPrice":50.08,"timestamp":1787342400000,"preClose":51.78,"halted":0,"volume":487921,"hourTrading":{"tag":"盘前","latestPrice":53.775,"preClose":50.08,"latestTime":"04:01 EDT","volume":2,"amount":105.375,"timestamp":1787558464318,"change":3.695,"changeRate":0.073782,"amplitude":0},"delay":0,"changeRate":-0.03283120896098885,"floatShares":305783111,"shares":305783111,"eps":2.229761,"marketStatus":"Pre-Mkt","change":-1.7,"latestTime":"08-24 05:06:08 EDT","open":51.91,"high":51.91,"low":50.025,"amount":24657789.365397997,"amplitude":0.036404,"askPrice":51.45,"askSize":9,"bidPrice":32,"bidSize":18,"shortable":3,"etf":0,"ttmEps":2.229761,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787578200000},"marketStatusCode":1,"adr":0,"exchange":"NYSE","adjPreClose":50.08,"dividendRate":0.042108,"preHourTrading":{"tag":"盘前","latestPrice":53.775,"preClose":50.08,"latestTime":"04:01 EDT","volume":2,"amount":105.375,"timestamp":1787558464318,"change":3.695,"changeRate":0.073782,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":51.05,"preClose":50.08,"latestTime":"19:30 EDT","volume":175258,"amount":8787992.254964,"timestamp":1787355005298,"change":0.97,"changeRate":0.019369,"amplitude":0.019369},"volumeRatio":1.7497389305446422,"impliedVol":0.0649,"impliedVolPercentile":0.168},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMA\",,,,,undefined,":{"symbol":"EMA","floatShares":305783111,"roa":"2.91%","roe":"7.56%","lyrEps":2.465138,"volumeRatio":1.7497389305446422,"shares":305783111,"dividePrice":2.111483,"high":51.91,"amplitude":0.036404,"preClose":51.78,"low":50.025,"week52Low":45.77,"pbRate":"1.64","psRate":"2.37","week52High":55.49,"institutionHeld":0,"latestPrice":50.08,"committee":0.333333,"eps":2.229761,"divideRate":0.042162,"volume":487921,"delay":0,"ttmEps":2.229761,"open":51.91,"prevYearClose":49.24,"prevWeekClose":50.08,"prevMonthClose":53.89,"prevQuarterClose":53.02,"fiveDayClose":51.51,"twentyDayClose":54.95,"sixtyDayClose":53.63,"dividendPayoutRate":0.8394110571990734,"dividendFrequency":"Q","dividendGrowthYears":0,"fiveYearAvgDividendRate":0.04206805783252231},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EMA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-07","symbol":"EMA","fiscalQuarterEnding":"2026/06","expectedEps":0.51,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786075200000,"reportTimeType":"pre","actualEps":0.5},{"date":"2026-08-03","symbol":"EMA","amount":0.7325,"announcedDate":"2026-07-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-03","defaultRemindTime":1785763800000,"name":"Emera Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-17","payableDate":"2026-08-03","currency":"CAD","dateTimestamp":1785729600000,"payDate":"2026-08-17"},{"market":"US","date":"2026-05-08","symbol":"EMA","fiscalQuarterEnding":"2026/03","expectedEps":0.89,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778212800000,"reportTimeType":"pre","actualEps":1},{"date":"2026-05-01","symbol":"EMA","amount":0.7325,"announcedDate":"2026-04-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-05-01","defaultRemindTime":1777642200000,"name":"Emera Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-05-15","payableDate":"2026-05-01","currency":"CAD","dateTimestamp":1777608000000,"payDate":"2026-05-15"},{"market":"US","date":"2026-02-23","symbol":"EMA","fiscalQuarterEnding":"2025/12","expectedEps":0.43,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1771822800000,"reportTimeType":"pre","actualEps":0.4}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EMA\",market:\"US\",,,undefined,":[{"executeDate":"2016-10-28","recordDate":"2016-11-01","paymentDate":"2016-11-15","value":0.3880294,"currency":"USD"},{"executeDate":"2025-08-01","recordDate":"2025-08-01","paymentDate":"2025-08-15","value":0.725,"currency":"CAD"},{"executeDate":"2025-10-31","recordDate":"2025-10-31","paymentDate":"2025-11-14","value":0.7325,"currency":"CAD"},{"executeDate":"2026-01-30","recordDate":"2026-01-30","paymentDate":"2026-02-13","value":0.7325,"currency":"CAD"},{"executeDate":"2026-05-01","recordDate":"2026-05-01","paymentDate":"2026-05-15","value":0.7325,"currency":"CAD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EMA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":1,"updateTime":1778299200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EMA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EMA","date":"2026-08-21","current":22.459806,"percent":0.843648,"low":16.637027,"twenty":17.635291,"median":20.20188,"eighty":21.05159,"high":22.07626,"avg":19.793468,"sd":1.503181,"marketCap":15955602988.26},"quantilePoints":[{"date":"2025-05-30","current":19.76944,"twenty":19.76944,"median":19.76944,"eighty":19.76944,"marketCap":13505496352.43},{"date":"2025-06-06","current":19.324012,"twenty":19.535669,"median":19.692043,"eighty":19.76944,"marketCap":13350532994.37},{"date":"2025-06-13","current":19.308216,"twenty":19.137627,"median":19.324012,"eighty":19.722054,"marketCap":13371262392.6},{"date":"2025-06-20","current":19.245035,"twenty":19.160372,"median":19.387193,"eighty":19.674036,"marketCap":13211518175.96},{"date":"2025-06-27","current":19.308216,"twenty":19.224185,"median":19.382455,"eighty":19.560942,"marketCap":13348226238.04},{"date":"2025-07-03","current":19.469329,"twenty":19.242508,"median":19.399829,"eighty":19.679723,"marketCap":13533023992.92},{"date":"2025-07-11","current":19.753645,"twenty":19.282944,"median":19.43142,"eighty":19.706259,"marketCap":13611556279.78},{"date":"2025-07-18","current":19.592532,"twenty":19.308216,"median":19.502499,"eighty":19.712577,"marketCap":13439260670.95},{"date":"2025-07-25","current":20.116937,"twenty":19.317694,"median":19.614646,"eighty":19.767545,"marketCap":13920070443.21},{"date":"2025-08-01","current":20.552889,"twenty":19.356234,"median":19.663612,"eighty":19.931816,"marketCap":14004388886.88},{"date":"2025-08-08","current":20.884591,"twenty":19.383402,"median":19.706259,"eighty":20.124519,"marketCap":14315223696.17},{"date":"2025-08-15","current":20.686356,"twenty":19.389088,"median":19.714157,"eighty":20.375981,"marketCap":14241020029.57},{"date":"2025-08-22","current":21.111677,"twenty":19.401724,"median":19.753645,"eighty":20.511821,"marketCap":14434555399.62},{"date":"2025-08-29","current":20.468969,"twenty":19.420679,"median":19.785235,"eighty":20.581071,"marketCap":14130173597.74},{"date":"2025-09-05","current":20.484722,"twenty":19.429525,"median":19.883167,"eighty":20.585711,"marketCap":14060435241.25},{"date":"2025-09-12","current":20.283088,"twenty":19.441529,"median":20.015847,"eighty":20.549566,"marketCap":13928376571.28},{"date":"2025-09-19","current":19.923928,"twenty":19.461747,"median":20.073945,"eighty":20.542062,"marketCap":13714455884.59},{"date":"2025-09-26","current":20.585539,"twenty":19.495865,"median":20.087756,"eighty":20.542062,"marketCap":14040465233.16},{"date":"2025-10-03","current":21.108526,"twenty":19.558414,"median":20.183278,"eighty":20.617044,"marketCap":14341364686.36},{"date":"2025-10-10","current":21.127429,"twenty":19.601378,"median":20.281209,"eighty":20.758818,"marketCap":14318469638.17},{"date":"2025-10-17","current":21.666169,"twenty":19.623491,"median":20.300416,"eighty":20.797254,"marketCap":14653790731.95},{"date":"2025-10-24","current":21.757535,"twenty":19.646868,"median":20.374454,"eighty":20.916344,"marketCap":14770054950.94},{"date":"2025-10-31","current":21.360568,"twenty":19.663296,"median":20.386244,"eighty":21.06631,"marketCap":14513331426.12},{"date":"2025-11-07","current":21.272354,"twenty":19.674036,"median":20.41226,"eighty":21.097184,"marketCap":14296037747.86},{"date":"2025-11-14","current":17.374062,"twenty":19.601378,"median":20.386244,"eighty":21.06631,"marketCap":14568586353.81},{"date":"2025-11-21","current":17.212836,"twenty":19.441529,"median":20.374454,"eighty":21.041735,"marketCap":14368588864.66},{"date":"2025-11-28","current":17.407331,"twenty":19.394143,"median":20.301992,"eighty":21.030393,"marketCap":14577653448.13},{"date":"2025-12-05","current":16.921093,"twenty":19.311375,"median":20.282148,"eighty":21.003928,"marketCap":14257439118.84},{"date":"2025-12-12","current":16.693329,"twenty":19.18059,"median":20.230664,"eighty":20.983135,"marketCap":14234564864},{"date":"2025-12-19","current":17.167393,"twenty":17.900621,"median":20.102346,"eighty":20.957301,"marketCap":14657419004.37},{"date":"2025-12-26","current":17.216186,"twenty":17.458514,"median":20.073945,"eighty":20.944699,"marketCap":14789996894.17},{"date":"2026-01-02","current":17.370269,"twenty":17.373303,"median":20.0392,"eighty":20.932097,"marketCap":14871263471.89},{"date":"2026-01-09","current":17.43447,"twenty":17.368214,"median":19.923928,"eighty":20.903742,"marketCap":14773589152.84},{"date":"2026-01-16","current":17.439606,"twenty":17.353836,"median":19.83736,"eighty":20.887161,"marketCap":14748903694.51},{"date":"2026-01-23","current":17.57828,"twenty":17.358457,"median":19.76786,"eighty":20.862056,"marketCap":14967122519.73},{"date":"2026-01-30","current":17.452446,"twenty":17.36616,"median":19.731531,"eighty":20.822459,"marketCap":15149245081.41},{"date":"2026-02-06","current":17.639913,"twenty":17.358457,"median":19.706259,"eighty":20.792844,"marketCap":15150466223.22},{"date":"2026-02-13","current":17.632209,"twenty":17.329694,"median":19.687304,"eighty":20.780241,"marketCap":15197950382.19},{"date":"2026-02-20","current":18.01228,"twenty":17.336884,"median":19.662032,"eighty":20.776461,"marketCap":15461241242.05},{"date":"2026-02-27","current":19.370854,"twenty":17.349212,"median":19.603589,"eighty":20.77079,"marketCap":15419204876.87},{"date":"2026-03-06","current":19.860551,"twenty":17.357687,"median":19.614646,"eighty":20.758818,"marketCap":15772457447.89},{"date":"2026-03-13","current":20.172176,"twenty":17.364105,"median":19.663612,"eighty":20.731723,"marketCap":16126249798.12},{"date":"2026-03-20","current":19.982975,"twenty":17.371786,"median":19.706259,"eighty":20.697698,"marketCap":15868293252.05},{"date":"2026-03-27","current":19.866116,"twenty":17.374599,"median":19.676248,"eighty":20.661152,"marketCap":15623406729.11},{"date":"2026-04-02","current":20.186088,"twenty":17.375919,"median":19.706259,"eighty":20.620195,"marketCap":15797694590.77},{"date":"2026-04-10","current":20.433719,"twenty":17.383333,"median":19.710303,"eighty":20.603182,"marketCap":16095943521.79},{"date":"2026-04-17","current":20.225489,"twenty":17.405284,"median":19.739002,"eighty":20.583555,"marketCap":16062393790.34},{"date":"2026-04-24","current":20.11598,"twenty":17.412759,"median":19.756565,"eighty":20.571074,"marketCap":16011506016.84},{"date":"2026-05-01","current":20.349038,"twenty":17.435497,"median":19.769087,"eighty":20.551228,"marketCap":16279588937.86},{"date":"2026-05-08","current":20.003663,"twenty":17.442174,"median":19.801031,"eighty":20.543322,"marketCap":15972071463.03},{"date":"2026-05-15","current":20.526748,"twenty":17.453473,"median":19.863334,"eighty":20.551228,"marketCap":15993082457.11},{"date":"2026-05-22","current":20.821212,"twenty":17.457768,"median":19.873689,"eighty":20.574777,"marketCap":16159791825.34},{"date":"2026-05-29","current":20.784047,"twenty":17.458514,"median":19.874498,"eighty":20.606796,"marketCap":16109213261.77},{"date":"2026-06-05","current":20.455276,"twenty":17.46015,"median":19.931505,"eighty":20.606796,"marketCap":15744335184.44},{"date":"2026-06-12","current":20.798341,"twenty":17.481546,"median":19.990575,"eighty":20.612514,"marketCap":15890994194.64},{"date":"2026-06-18","current":20.901261,"twenty":17.493192,"median":20.015847,"eighty":20.650154,"marketCap":15823421326.33},{"date":"2026-06-26","current":21.595968,"twenty":17.496103,"median":20.061717,"eighty":20.767009,"marketCap":16281617755.86},{"date":"2026-07-02","current":21.507343,"twenty":17.504259,"median":20.064683,"eighty":20.784032,"marketCap":16222688501.02},{"date":"2026-07-10","current":21.544508,"twenty":17.526194,"median":20.082188,"eighty":20.821212,"marketCap":16271827884.13},{"date":"2026-07-17","current":21.936175,"twenty":17.541814,"median":20.087829,"eighty":20.898969,"marketCap":16718811747.19},{"date":"2026-07-24","current":22.07626,"twenty":17.564926,"median":20.116937,"eighty":20.951,"marketCap":16761941188.16},{"date":"2026-07-31","current":21.66744,"twenty":17.586675,"median":20.124404,"eighty":21.004011,"marketCap":16545696607.24},{"date":"2026-08-07","current":20.666833,"twenty":17.604226,"median":20.156816,"eighty":21.026741,"marketCap":15758445214.07},{"date":"2026-08-14","current":21.122954,"twenty":17.619883,"median":20.180562,"eighty":21.040346,"marketCap":15758083883.88},{"date":"2026-08-21","current":21.131815,"twenty":17.635291,"median":20.20188,"eighty":21.05159,"marketCap":15955602988.26}],"updateTime":1787530397351},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EMA\",pageSize:20,pageCount:10,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2629009215","title":"Press Release: Ipsen delivers strong sales in the first quarter of 2026 and confirms its full-year guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2629009215","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629009215?lang=en_us&edition=fundamental","pubTime":"2026-04-23 13:00","pubTimestamp":1776920400,"startTime":"0","endTime":"0","summary":"-- Total sales growth of 22.6% at CER1 or 17.0% as reported, driven by all. three therapeutic areas, with accelerating portfolio momentum outside. -- Strong pipeline momentum with three Phase III readouts expected in H2. PARIS, FRANCE, 23 April 2026 - Ipsen , a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2026.\"Ipsen has delivered a strong start to 2026,\" said David Loew, Chief Executive Officer, Ipsen. \"We advanced our strategic priorities across the business, combining strong top--line performance with continued pipeline progress. I am very pleased with the growth of our rare liver disease franchise with the performance of Iqirvo and Bylvay. Additionally, with three Phase III readouts expected this year and three new late-stage programs starting, Ipsen is well-positioned to drive sustainable growth and deliver meaningful value for patients.\". Ipsen is confirming its financial guidance for full-year 2026:. Ipsen anticipates several","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4087","BK4201","BK4081","R","CHMP","BK4232","BK4022","EMA","EC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629022826","title":"Bitcoin, Ethereum, XRP, Dogecoin Up 3% As Markets Hope For Iran War Settlement","url":"https://stock-news.laohu8.com/highlight/detail?id=2629022826","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629022826?lang=en_us&edition=fundamental","pubTime":"2026-04-23 03:09","pubTimestamp":1776884959,"startTime":"0","endTime":"0","summary":"Bitcoin is nearing $79,000, supported by fresh hopes about a settlement in the Iran war.","market":"nz","thumbnail":"https://www.benzinga.com/files/images/story/2026/04/22/Futuristic-Crypto-Trading-Floor-Bustling.jpeg","type":0,"news_type":0,"thumbnails":["https://www.benzinga.com/files/images/story/2026/04/22/Futuristic-Crypto-Trading-Floor-Bustling.jpeg"],"rights":{"source":"Benzinga","url":"https://www.benzinga.com/crypto/cryptocurrency/26/04/51981463/bitcoin-ethereum-xrp-dogecoin-up-3-as-markets-hope-for-iran-war-settlement","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/crypto/cryptocurrency/26/04/51981463/bitcoin-ethereum-xrp-dogecoin-up-3-as-markets-hope-for-iran-war-settlement","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"Benzinga","symbols":["IBIT","GDOG","BK4601","BKCH","BTF","BETE","BK4585","CETH","DOJE","FETH","ETU","BITW","XRPZ","BITQ","YETH","XRPT","TXXD","ETHU","ETHV","EZET","QETH","BWOW","XRP","HOPE","XXRP","ETHD","ETHW","STCE","EETH","ETHA","BK4588","BK4211","TOXR","UXRP","XRPC","GDLC","BEGS","LFGY","ETHE","ETHT","BK4081","XRPI","EMA","BETH","ETH","BK4594"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629727041","title":"Capricor Therapeutics Announces Late-Breaking Presentation of HOPE-3 Phase 3 Results at the American Academy of Neurology 2026 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2629727041","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629727041?lang=en_us&edition=fundamental","pubTime":"2026-04-22 21:00","pubTimestamp":1776862800,"startTime":"0","endTime":"0","summary":"SAN DIEGO, April  22, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today anno","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/22/3279030/0/en/Capricor-Therapeutics-Announces-Late-Breaking-Presentation-of-HOPE-3-Phase-3-Results-at-the-American-Academy-of-Neurology-2026-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AFG","BK4081","BK4139","BK4178","BK4117","CAPR","AAN","HOPE","BK4211","ATMP","EMA","BK4107"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629722127","title":"Emera price target raised to C$73 from C$72 at CIBC","url":"https://stock-news.laohu8.com/highlight/detail?id=2629722127","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629722127?lang=en_us&edition=fundamental","pubTime":"2026-04-20 23:56","pubTimestamp":1776700584,"startTime":"0","endTime":"0","summary":"CIBC raised the firm’s price target on Emera (EMA) to C$73 from C$72 and keeps a Neutral rating on the shares. Published first on TheFly – the ulti...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/emera-price-target-raised-to-c73-from-c72-at-cibc-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/emera-price-target-raised-to-c73-from-c72-at-cibc-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EMA","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628476267","title":"S&P 500 Futures Drop In Premarket Trading; TopBuild, Imperial Oil Lead","url":"https://stock-news.laohu8.com/highlight/detail?id=2628476267","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628476267?lang=en_us&edition=fundamental","pubTime":"2026-04-20 19:30","pubTimestamp":1776684600,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Barrons.com using technology from Automated Insights.With U.S. stock markets set to open in two hours, TopBuild Corp.  was up 18.4% in pre-market trading, and Imperial Oil Ltd.  was up 6.6%.Marvell Technology Inc. , GlobalFoundries Inc. , and Emera Inc.  were all posting gains of at least 5%. In early trading, AST SpaceMobile Inc.  and Bank of Nova Scotia  had posted declines, falling 15.0% and 13.4%, respectively.Meanwhile S&P 500 futures were down 0.51%, with futures for the Dow Jones Industrial Average falling 0.58%. The Cboe Volatility Index futures were down 0.24%.In commodities news, Brent crude oil futures were up 5.43%, and gold futures were down 1.48%. Bitcoin was up 0.29% to $75,213.In the previous regular trading session, the S&P 500 and the Dow were up 1.20% and 1.79%, respectively. Stocks in Asia were up overnight, with Japan's NIKKEI 225 Index up 0.60% and China's Shanghai Composite Index rising 0.76%.U.S. stock markets open for","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1992135472.HKD","BK4089","IVE","LU0056508442.USD","LU1169589451.USD","ETFT","ESmain","BK4585","LU2931357623.SGD","SPXU","LU1992135399.USD","LU0642271901.SGD","LU2357305700.SGD","SPYV","LU1316542783.SGD","SSO","VV","LU1989764748.USD","IE00BBT3K403.USD","BK4550","JEPI","NOBL","ASTX","SPYU","MRVL","BLD","BK4588","BK4201","IE00BLSP4452.SGD","VTV","LU2290526834.HKD","LU1989764664.SGD","LU0444973449.USD","GPIX","LU1303367103.USD","SPUS","MOAT","BK4559","GFS","IVV","SPYG","LU1720051017.SGD","LU0187121727.USD","BK4081","IE00BMPRXR70.SGD","IE00BLSP4239.USD","LU2322448957.HKD","EMA","BK4504","LU2360107168.USD","IVW","SH","VTI","LU1084165304.USD","BMAY","IJR","VBK","MRVU","LU1169590202.USD","UPRO","SDS","BK4515",".SPX","IE00BMPRXN33.USD","OEX","LU1852331112.SGD","SPGP","SPYI","XLG","LU0444971666.USD","LU1119994496.HKD","SPUU","RSP","LU1235294995.USD","LU1823568750.SGD","IE0009354923.USD","LU1046421795.USD","SPDN","LU1861215975.USD","LU0127658192.USD","LU2272731782.SGD","SPHD","HIBL","ASTN","LU0476273544.USD","SFY","LU1261432733.SGD","LU0081259029.USD","SPMO","BK4141","LU0154236417.USD","MVLL","XDTE","LU1720051108.HKD","LU2458330243.SGD","SPLV","SPYD","SPYQ","BK4088","LU1861220033.SGD","BNS","SCHX","ALLW","ASTS","LU2089985449.USD","BK4604","IJH","IMO","BK4543","LU1548497426.USD","SPHQ","BK4605","ITOT","LU2272731600.USD","BK4581","VEU","LU1815336760.USD","SG9999000418.SGD","BK4534","XYLD","LU2098885051.SGD","GSLC","DBSC","MESmain","TSPY","LU2458330169.SGD","LU0957808578.USD","YSPY","LU2473716301.USD","LU2244417387.USD","SPYM","HIBS","LU0061475181.USD","LU1642822529.SGD","LU2272731865.HKD","BK4207","SCHB","LU0274383776.USD","SPXS","LU0786609619.USD","IE00BN8TJ469.HKD","ACWI","SPXL","OEF","LU2322448791.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629727360","title":"Singapore procuring more LNG as Iran war cuts some supply","url":"https://stock-news.laohu8.com/highlight/detail?id=2629727360","media":"Sing Yee Ong & Stephen Stapczynski / Bloomberg","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629727360?lang=en_us&edition=fundamental","pubTime":"2026-04-20 04:19","pubTimestamp":1776629975,"startTime":"0","endTime":"0","summary":"Singapore uses the fossil fuel as its main source for power generation and gets about 60% of its imports in the form of seaborne LNG shipments.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"edge_highlight","url":"https://www.theedgesingapore.com/news/oil-gas/singapore-procuring-more-lng-iran-war-cuts-some-supply?utm_source=Blog&utm_medium=RSS&utm_campaign=Tiger_Brokers_app_RSS","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theedgesingapore.com/news/oil-gas/singapore-procuring-more-lng-iran-war-cuts-some-supply?utm_source=Blog&utm_medium=RSS&utm_campaign=Tiger_Brokers_app_RSS","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"edge_highlight","symbols":["LU0345770308.USD","LU0742534661.SGD","LU0630314457.HKD","LU0048573561.USD","LU0314104364.USD","ERX","LU0345780950.USD","LU1621767737.EUR","VDE","LNG","LU1621767810.EUR","BK4585","IE00B29SXK94.USD","LU0251131958.USD","EMA","BK4081","LU0122376428.USD","LU0788109394.HKD","LU1621768206.USD","BK4144","BK4588","LU0345770993.USD","IE00B29SXL02.USD","LU0368265418.SGD","LU0345781412.USD","LU2449327464.USD","LU2384288077.EUR","LU1621768115.EUR","LU2211815571.USD","LU0170899867.USD","LU0251142724.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186465286","title":"Roche Initiates New Study for Elevidys Gene Therapy Following European Regulatory Feedback","url":"https://stock-news.laohu8.com/highlight/detail?id=1186465286","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186465286?lang=en_us&edition=fundamental","pubTime":"2026-04-16 20:50","pubTimestamp":1776343827,"startTime":"0","endTime":"0","summary":"Roche announced on Thursday that it will commence a late-stage clinical trial for its gene therapy Elevidys after receiving feedback from European drug regulators. The therapy, developed in...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627343612","title":"Press Release: Emera Incorporated Announces Dividend Rates for Series J and Series K First Preferred Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2627343612","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627343612?lang=en_us&edition=fundamental","pubTime":"2026-04-16 01:54","pubTimestamp":1776275640,"startTime":"0","endTime":"0","summary":"Emera Incorporated   announced today the applicable dividend rates for its Cumulative Minimum Rate Reset First Preferred Shares, Series J  and Cumulative Floating Rate First Preferred Shares, Series K , in each case, payable if, as and when declared by the Board of Directors of the Company:. quarter), being equal to the sum of the Government of Canada bond yield. as at April 15, 2026, plus 3.28%, payable quarterly on the 15th of. February, May, August and November of each year during the five-year. period commencing on May 15, 2026 and ending on  May. per Series K Share for the quarter), being equal to the sum of the. elapsed during the quarter divided by 365), payable on the 15th of August,Series J Shares will not be entitled to convert their shares into Series. outstanding less than 1,000,000 Series J Shares on the Conversion Date,In either case, the Company will give written notice to that effect to the holders of Series J Shares at least seven days prior to the Conversion Date, sub","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627239787","title":"Why Infleqtion Stock Trading Higher On Wednesday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2627239787","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627239787?lang=en_us&edition=fundamental","pubTime":"2026-04-16 00:58","pubTimestamp":1776272280,"startTime":"0","endTime":"0","summary":"Infleqtion Inc (NYSE: INFQ) shares surge as Nvidia launches its Ising quantum AI models. Discover how this partnership is transforming the quantum computing landscape.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/04/15/Candlestick-Graph-Chart-Of-Stock-And-For.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/04/15/Candlestick-Graph-Chart-Of-Stock-And-For.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/movers/26/04/51838352/why-infleqtion-stock-trading-higher-on-wednesday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/04/51838352/why-infleqtion-stock-trading-higher-on-wednesday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4217","BK4081","EMA","BK4170","INFQ","SMA","QPUX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627462934","title":"Suzhou Ribo Advances Lead siRNA Anticoagulant With EMA Phase 2b Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2627462934","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627462934?lang=en_us&edition=fundamental","pubTime":"2026-04-14 08:10","pubTimestamp":1776125450,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science Co., Ltd. Class H ( ($HK:6938) ) has provided an announcement. Suzhou Ribo Life Science has submitted a phase 2b clinical ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/suzhou-ribo-advances-lead-sirna-anticoagulant-with-ema-phase-2b-filing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/suzhou-ribo-advances-lead-sirna-anticoagulant-with-ema-phase-2b-filing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4081","DBB","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627434048","title":"Emera Maintains Quarterly Dividend at $0.7325 per Share; Payable Around May 15 to Shareholders of Record on May 1","url":"https://stock-news.laohu8.com/highlight/detail?id=2627434048","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627434048?lang=en_us&edition=fundamental","pubTime":"2026-04-13 18:52","pubTimestamp":1776077532,"startTime":"0","endTime":"0","summary":"Emera Maintains Quarterly Dividend at $0.7325 per Share; Payable Around May 15 to Shareholders of Record on May 1","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4081","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627434127","title":"Press Release: Emera Declares Quarterly Dividends","url":"https://stock-news.laohu8.com/highlight/detail?id=2627434127","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627434127?lang=en_us&edition=fundamental","pubTime":"2026-04-13 18:43","pubTimestamp":1776076980,"startTime":"0","endTime":"0","summary":"On April 13, 2026, the Board of Directors of Emera Inc.  declared quarterly dividends on its common shares and First Preferred Shares, each of which is payable on and after May 15, 2026 to the applicable shareholders of record at the close of business on May 1, 2026, as follows:. Emera Inc. hereby notifies the shareholders of its common shares and its First Preferred Shares that such dividends declared qualify as eligible dividends pursuant to the Income Tax Act  and corresponding provincial legislation.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625931887","title":"Press Release: Emera Teleconference on May 8 to Discuss Q1 2026 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2625931887","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625931887?lang=en_us&edition=fundamental","pubTime":"2026-04-07 18:00","pubTimestamp":1775556000,"startTime":"0","endTime":"0","summary":"Today Emera  announced that it will release its Q1 2026 results on Friday, May 8, 2026, before markets open. The Company will host a teleconference and webcast the same day at 9:30 a.m. Atlantic  to discuss the results.Analysts and other interested parties in North America are invited to participate by dialing 1-800-717-1738. International parties are invited to participate by dialing 1-289-514-5100. Participants should dial in at least 10 minutes prior to the start of the call. No pass code is required.A live and archived audio webcast of the teleconference will be available on the Company's website, www.emera.com. A replay of the teleconference will be available on the Company's website two hours after the conclusion of the call.Emera  is a leading North American provider of energy services headquartered in Halifax, Nova Scotia, with investments in regulated electric and natural gas utilities, and related businesses and assets. The Emera family of companies delivers safe, reliable en","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4081","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625395933","title":"Oculis to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2625395933","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625395933?lang=en_us&edition=fundamental","pubTime":"2026-04-07 16:00","pubTimestamp":1775548800,"startTime":"0","endTime":"0","summary":"ZUG, Switzerland, April  07, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophth","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/07/3268862/0/en/Oculis-to-Participate-in-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA","LU2357305700.SGD","LU2360107325.USD","LU1861214812.USD","LU1548497426.USD","BK4081","IE00BZ199S13.USD","LU1854103824.USD","BK4588","IE00BFMHRM44.USD","LU1861219969.SGD","OCS","ON","LU1854104046.USD","LU1978683503.SGD","IE00BD6J9T35.USD","LU1720051017.SGD","LU2298322129.HKD","BK4605","BK4007","BK4512","LU1861215975.USD","LU1861220033.SGD","LU0348723411.USD","BK4141","LU0124384867.USD","LU1720051108.HKD","BK4585","LU0724618433.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624381694","title":"How Investors Are Reacting To Teva (TEVA) Advancing Its Biosimilar Pipeline With New FDA and EMA Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2624381694","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624381694?lang=en_us&edition=fundamental","pubTime":"2026-04-04 15:17","pubTimestamp":1775287031,"startTime":"0","endTime":"0","summary":"In late March 2026, Teva Pharmaceutical Industries reported three biosimilar milestones, including US FDA approval of PONLIMSI (denosumab-adet) as a biosimilar to Prolia for all its osteoporosis-related indications, alongside FDA and EMA acceptance of filings for a proposed Xolair (omalizumab) biosimilar across its full label.\nThese advances highlight Teva’s effort to broaden its higher-value biopharmaceutical portfolio, using biosimilars to complement its generics base and support its Pivot...","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/308047-main-header/1585187365850","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/308047-main-header/1585187365850"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-teva/teva-pharmaceutical-industries/news/how-investors-are-reacting-to-teva-teva-advancing-its-biosim","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-teva/teva-pharmaceutical-industries/news/how-investors-are-reacting-to-teva-teva-advancing-its-biosim","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["AIPO","BK4007","TEVA","BK4585","LU2324357040.USD","ISBC","BK4566","LU1983299246.USD","BK4584","EMA","BK4081","BK4559","BK4596","BK4211","BK4588","BK4557","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624664666","title":"Is EMA Validation Of Taletrectinib Expanding Nuvation Bio’s (NUVB) Targeted Lung Cancer Opportunity?","url":"https://stock-news.laohu8.com/highlight/detail?id=2624664666","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624664666?lang=en_us&edition=fundamental","pubTime":"2026-04-04 03:24","pubTimestamp":1775244283,"startTime":"0","endTime":"0","summary":"In March 2026, Eisai and Nuvation Bio reported that the European Medicines Agency validated their Marketing Authorisation Application for taletrectinib to treat advanced ROS1-positive non-small cell lung cancer, following existing approvals in the US, China and Japan.\nThis regulatory milestone could broaden taletrectinib’s geographic reach under Eisai’s licensing deal, potentially deepening Nuvation Bio’s role in targeted lung cancer treatment across Europe and other Eisai territories.\nWe’ll...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nuvb/nuvation-bio/news/is-ema-validation-of-taletrectinib-expanding-nuvation-bios-n","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nuvb/nuvation-bio/news/is-ema-validation-of-taletrectinib-expanding-nuvation-bios-n","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["EMA","NUVB","BK4007","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181820253","title":"ABBISKO-B Shares Surge Nearly 10% on EMA Orphan Drug Designation for FGFR4 Inhibitor","url":"https://stock-news.laohu8.com/highlight/detail?id=1181820253","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181820253?lang=en_us&edition=fundamental","pubTime":"2026-04-01 16:00","pubTimestamp":1775030422,"startTime":"0","endTime":"0","summary":"ABBISKO-B (02256) saw its shares climb over 10% during the trading session. At the time of writing, the stock was up 8.44%, trading at HK$13.11, with a turnover of HK$34.2099 million. The increase...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","BK4585","EMA","LU2476274720.SGD","LU2778985437.USD","BK1161","IE00B5MMRT66.SGD","IE00B543WZ88.USD","02256","LU2476274308.USD","VXUS","BK4081","BK4588","IE00BPRC5H50.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624537869","title":"Press Release: BrainStorm Cell Therapeutics Announces Full Year 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2624537869","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624537869?lang=en_us&edition=fundamental","pubTime":"2026-04-01 04:01","pubTimestamp":1774987260,"startTime":"0","endTime":"0","summary":"Strategic $2.0 million post year-end financing and re-rating of BCLI shares underscore market confidence. Company highlights durable long-term survival in Expanded Access Program  cohort supporting Phase 3b patient selection and inclusion criteria. NEW YORK, March 31, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the full year ended December 31, 2025, and provided a corporate update.-- A Citizen Petition was filed with the FDA by representatives of the ALS. community. The petition requests a renewed regulatory review of the data. supporting NurOwn. BrainStorm acknowledges the petition as a constructive. development that underscores the continued interest in NurOwn's potential. therapeutic value. The Company did not participate in the drafting or. -- In the Expanded Access Program , 50% of patients  remain alive","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1732799900.SGD","LABU","LU2357305700.SGD","BK4534","LU2111349929.HKD","NPW.SI","BK4139","LU1989772923.USD","LU0320765646.SGD","LU1244550221.USD","BK4127","BK4585","BK4081","LU0006306889.USD","EMA","LU0314104364.USD","LU2271345857.HKD","BCLI","LU0267386448.USD","LU1548497426.USD","LU0225283273.USD","LU0795875169.SGD","BK4007","IE00BKVL7J92.USD","LU0098860793.USD","LU1074936037.SGD","LU1363072403.SGD","LU2347655156.SGD","R","LU2023251221.USD","LU1732800096.USD","LU1720051017.SGD","LU1244550494.USD","BK4516","LU2028103732.USD","BK6507","LU1668664300.SGD","LU1989772840.SGD","LU0106261372.USD","BK4588","LU1162221912.USD","LENZ","BK4022","LU0971096721.USD","BK4539","LU2089284900.SGD","LU0106831901.USD","LU0882574139.USD","BK4504","BK4232"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624562539","title":"Abbisko Wins EMA Orphan Drug Status for Liver Cancer Therapy Irpagratinib","url":"https://stock-news.laohu8.com/highlight/detail?id=2624562539","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624562539?lang=en_us&edition=fundamental","pubTime":"2026-04-01 00:37","pubTimestamp":1774975066,"startTime":"0","endTime":"0","summary":"Abbisko Cayman Limited ( ($HK:2256) ) just unveiled an announcement. Abbisko Therapeutics, a subsidiary of Abbisko Cayman Limited, has developed ir...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/abbisko-wins-ema-orphan-drug-status-for-liver-cancer-therapy-irpagratinib?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/abbisko-wins-ema-orphan-drug-status-for-liver-cancer-therapy-irpagratinib?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EMA","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144999099","title":"ABBISKO-B (02256): FGFR4 Inhibitor Irpagratinib Receives Orphan Drug Designation from EMA for Hepatocellular Carcinoma Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1144999099","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144999099?lang=en_us&edition=fundamental","pubTime":"2026-03-31 20:38","pubTimestamp":1774960711,"startTime":"0","endTime":"0","summary":"ABBISKO-B (02256) announced that its subsidiary, Shanghai Abbisko Biomedical Technology Co., Ltd. (Abbisko Medical), has received Orphan Drug Designation (ODD) from the European Medicines Agency...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2476274308.USD","LU2488822045.USD","IE00BPRC5H50.USD","02256","BK4081","LU2778985437.USD","EMA","IE00B543WZ88.USD","IE00B5MMRT66.SGD","LU2476274720.SGD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":10,"totalSize":200,"code":"91000000","status":"200"}]}}